A means for lubrication of the condom

 

(57) Abstract:

The invention relates to medicine and can be used for the prevention of sexually transmitted diseases. The inventive means for lubrication of the condom contains antiviral drug and pharmaceutically acceptable additives target. It additionally contains a stabilizer biological, physico-chemical properties and/or resistance to microbial contamination, immunomodulator and/or antimicrobial agent. As antiviral agents it contains alpha, or beta, or gamma interferon in the number 1000-10000000 ME on 1 g of product. Effect: expanding Arsenal of antiviral and antimicrobial agents for lubricating a condom. 16 C.p. f-crystals, 7 PL.

The invention relates to medicine and can be used for the prevention of sexually transmitted diseases.

Known and used in medical practice means for the prevention of sexually transmitted diseases.

In the patent RU 2031645, class a 61 K 7/48, 35/78 described antibacterial cream for genital cosmetics containing biologically active substances in the form of dry extracts mother is ed sexual intercourse in the vagina or the canal of the urethra, active only against bacterial infections and does not protect against AIDS.

For the prevention of HIV infection through sexual intercourse is known coating condom from inside and outside disinfectant (EP patent 0427997, CL 01 And F 31/00, 1991).

The closest in technical essence and the achieved result to the claimed invention is a means for lubrication of the condom containing a disinfectant and anti-inflammatory medication - menfegol based, and presented in the form of a gel or ointment (EP patent 0343631, class a 61 K 31/765, 1989).

However, the known tool is not effective.

The technical result of the claimed invention is an expanding Arsenal of domestic funds with highly effective antiviral and antimicrobial properties, in the form of a gel, ointment, cream or emulsion for lubrication of the condom.

To achieve the technical result means for lubrication of the condom containing antiviral drug and pharmaceutically acceptable additives target, according to the invention additionally contains a stabilizer biological, physico-chemical properties and/or resistance to microbial contamination, immunome is whether the beta, or gamma-interferon in the number 1000-10000000 ME on 1 g of product.

The tool contains a stabilizer biological, physico-chemical properties selected from the group: polyethylene oxide, glycerin, gelatin, polyvinylpyrrolidone, polyvinyl alcohol, a derivative of methyl cellulose in an amount of 0.0001-0.09 g per 1 g of product.

It additionally contains Trilon B and/or butylacetyl in the amount of 0.0001-0,0006 g per 1 g of product.

The tool contains a stabilizer resistance to microbial contamination, selected from the group of nipagin, Quaternary ammonium compounds, chlorhexidine.

As Quaternary ammonium compounds it contains atony, or benzathine chloride or benzalkonium chloride.

It contains immunomodulator selected from the group of cytokines, metronidazole, in the amount of 0.001-0.025 g per 1 g of product, Radostin in the number 0,006-0.04 g per 1 g of product, polyoxidonium in the amount of 0.003-0,012 g per 1 g of product, Poludan in the amount of 50-400 IU per 1 g of product, Amiksin in the amount of 0.005-0.015 g per 1 g of product.

As it contains cytokines interleukin-2 in the amount of 1000-20000 ME and/or tumor necrosis factor alpha or beta in the number 1000-10000000 ME on 1 g of product.

It contains an antimicrobial agent selected from the group Miramistin in the amount of 0.0001-0.04 g per 1 g of the agent, broad-spectrum antibiotics in the amount of 0.0001-0.04 g per 1 g of product, methylbenzethonium in the amount of a 0.012-0.025 g per 1 g of product, cetylpyridinium in the amount of 0.025-0.03 g per 1 g of product, alkyltrimethylammonium in the amount of 0.025-0.03 g per 1 g of product, chlorhexidine in an amount of 0.01-0.02 g per 1 g of product, iodopovidone in the amount of 0.025-0.035 g per 1 g of product, imidazolidinedione in an amount of 0.01-0.05 g per 1 g of product, diazolidinylurea in the amount of 0.001-0.05 g per 1 g of product.

It contains broad-spectrum antibiotics selected from the group: amoxicillin, ampicillin, oxacillin, methicillin, cephalexin.

As antimicrobial, Antiprotozoal and antifungal means it contains a silver-containing component in an amount of 0.001 to 0.15 g per 1 g of product.

The tool further comprises spermatocidal agent.

As spermatocide agent it contains nonoxynol 9 or octoxynol 9 in the amount of 0.005-0.05 g per 1 g of product.

It also contains vitamins selected from the group of: vitamin E, vitamin C, vitamin D3redtwo, selected from the group: diclofenac sodium, indomethacin, ibuprofen, naproxen, corticosteroids: hydrocortisone, perkantoran, triamcinolona in the amount of 0.001-0.15 g per 1 g of product.

As pharmaceutically acceptable target additives it contains one or more ingredients from the group of additives, including polyethylene oxide, oil, cocoa butter, paraffin, petrolatum, glycerin, lanolin, emulsifier, dimethyl sulfoxide, vegetable oil, flavourings.

A means for lubrication of the condom is an ointment, gel, cream or emulsion.

The invention is illustrated in the following examples.

Example 1. The technology of obtaining funds for lubrication of the condom.

To obtain gel prepare a solution of the stabilizer: 1% solution nipagina, 6% solution of the polyvinylpyrrolidone. Add interleukin-2, tumor necrosis factor and as a pharmaceutically acceptable target additive is a hydrophilic base composed of an alloy of polyethylene oxide 400 and 4000 polyethylene oxide. Mix the components, and sterilize by autoclaving. Then add alpha, or beta, or gamma-interferon and mix. Ready the product Packed in the required enkosi 1 g of product (see table.1).

Example 2. Carried out analogously to example 1, but in addition the composition is administered silver-containing component (havergal).

These components take in the ratio of 1 g of product (see table.2).

Example 3. For more ointment take stabilizer: polyvinyl alcohol, 10% solution etoniya. Add a 10% solution of the trylon B. Mix everything with indomethacin, metronidazole, Radostina, Miramistin, vitamins E, C3And PP , as well as pharmaceutically acceptable target additives - lipophilic base, consisting of lanolin and cocoa butter in a ratio of 6:1. Sterilize and add alpha-or beta-, or gamma-interferon and next, as in example 1.

These components take in the ratio of 1 g of product (see table.3).

Example 4. To prepare the cream mix the stabilizer solution NaKM (derived methylcellulose) and chlorhexidine with butylacetyl, then antibiotiki broad-spectrum mentioned above, spermacidal agent (nonoxynol 9 or octoxynol 9), ibuprofen, benzethonium, vitamin E, polyoxidonium, cetylpyridinium. Connect with gelatin, melted lipophilic basis as the pharmaceutical is it as in example 1.

These components take in the ratio of 1 g of product (see table.4).

Example 5. To prepare the cream mix the stabilizer solution N (derived methylcellulose) and chlorhexidine with butylacetyl, then imidazolidinedione, diazolidinylurea, spermacidal agent (nonoxynol 9 or octoxynol 9), diclofenac sodium, benzethonium, vitamin E, polyoxidonium, cetylpyridinium. Connect with gelatin, melted lipophilic basis as pharmaceutically acceptable target additives and then add alpha, or beta, or gamma-interferon. Next, as in example 1.

These components take in the ratio of 1 g of product (see table.5).

Example 6. To obtain Masi mix the stabilizer polyvinylpyrrolidone and benzalkonium chloride or benzathine chloride with Trilon B. Then add vitamin C, naproxen, Radostin, methylbenzethonium, iodopovidone. Mixed with Poludan, corticosteroid drugs and alkyltrimethylammonium. Combined with pharmaceutically acceptable targeted supplements - lipophilic-hydrophilic base composed of an alloy of lanolin and vaseline in soo on 1 g of the mixture (see table.6).

Example 7. To obtain emulsions of the mixed stabilizer - glycerine with atonium and Trilon B. Add Radostin, Poludan, Amiksin, forcertain or triamcinolon, iodopovidone, chlorhexidine. Mixed with pharmaceutically acceptable targeted supplements, representing, for example, an emulsion of cocoa butter, vaseline oil, paraffin, wax and distilled water taken in a ratio of 3:3:1:1:2. Then enter alpha-or beta-, or gamma-interferon.

These components take in the ratio of 1 g of product (see table.7).

The resulting tool has the form of ointments different consistency.

Laboratory testing tool on the model of cell cultures, experimental animals have shown that it is non-toxic, non-pyrogenic, retains its physico-chemical and biological properties. The introduction of Radostina increases the effectiveness of preventive and therapeutic action funds.

Clinical trials on human volunteers indicate that the tool is well transportable and does not cause allergic reactions,

The tool is recommended for the prevention and treatment of sexually transmitted diseases. mimie targeted supplements, characterized in that it additionally contains a stabilizer biological, physico-chemical properties and/or resistance to microbial contamination, immunomodulator and/or antimicrobial agent.

2. A means for lubrication of the condom under item 1, characterized in that as antiviral agents it contains alpha, or beta, or gamma interferon in the number 1000-10000000 ME on 1 g of product.

3. A means for lubrication of the condom under item 1, characterized in that it contains the stabilizer of biological, physico-chemical properties selected from the group: polyethylene oxide, glycerin, gelatin, polyvinylpyrrolidone, polyvinyl alcohol, a derivative of methyl cellulose in an amount of 0.0001-0,09 1 g of product.

4. A means for lubrication of the condom under item 1, characterized in that it further comprises Trilon B or butylacetyl in the amount of 0.0001-0,0006 g per 1 g of product.

5. A means for lubrication of the condom under item 1, characterized in that it contains the stabilizer of resistance to microbial contamination, selected from the group of nipagin, Quaternary ammonium compounds, chlorhexidine in the amount of 0.0001-0.01 g to 1 g of product.

6. A means for lubrication of the condom p is chloride, or benzalkonium chloride.

7. A means for lubrication of the condom under item 1, characterized in that it contains an immunomodulator selected from the group, cytokines, metronidazole in the amount of 0.001-0,025 1 g of product, Radostin in the number 0,006-0.04 g per 1 g of product, polyoxidonium in the amount of 0.003-0,012 g per 1 g of product, Poludan in the amount of 50-400 IU per 1 g of product, Amiksin in the amount of 0.005-0.015 g per 1 g of product.

8. Means for lubricating a condom on p. 7, characterized in that it contains cytokines interleukin - 2 in the amount of 1000-20000 ME and/or tumor necrosis factor alpha or beta in the number 1000-10000000 ME on 1 g of product.

9. A means for lubrication of the condom under item 1, characterized in that it contains an antimicrobial agent selected from the group: Miramistin in the amount of 0.0001-0.04 g per 1 g of the agent, broad-spectrum antibiotics in the amount of 0.0001-0.04 g per 1 g of product, methylbenzethonium in the amount of a 0.012-0.025 g per 1 g of product, cetylpyridinium in the amount of 0.025-0.03 g per 1 g of product, alkyltrimethylammonium in the amount of 0.025-0.03 g per 1 g of product, chlorhexidine in an amount of 0.01-0.02 g per 1 g of product, iodopovidone in the amount of 0.025-0.035 g per 1 g of product, imidazolidinedione in the share of the lubricant of the condom on p. 10, characterized in that it contains broad-spectrum antibiotics selected from the group: amoxicillin, ampicillin, oxacillin, methicillin, cephalexin.

11. A means for lubrication of the condom under item 1, characterized in that it further comprises as an Antiprotozoal and antifungal means of silver-containing component in an amount of 0.001 to 0.15 g per 1 g of product.

12. A means for lubrication of the condom under item 1, characterized in that it further comprises spermatocidal agent.

13. Means for lubricating a condom on p. 13, characterized in that as spermatocide agent it contains nonoxynol 9 or octoxynol 9 in the amount of 0.005-0.05 g per 1 g of product.

14. A means for lubrication of the condom under item 1, characterized in that it additionally contains vitamins selected from the group of: vitamin E, vitamin C, vitamin D3the vitamin e in the amount of 0.005-0.025 g per 1 g of product.

15. A means for lubrication of the condom under item 1, characterized in that it additionally contains anti-inflammatory agent selected from the group: diclofenac sodium, indomethacin, ibuprofen, naproxen, corticosteroids: hydrocortisone, perkantoran, trincea fact, as pharmaceutically acceptable target additives it contains one or more ingredients from the group of additives, including polyethylene oxide, oil, cocoa butter, paraffin, petrolatum, glycerin, lanolin, emulsifier, dimethyl sulfoxide, vegetable oil, flavourings.

17. A means for lubrication of the condom under item 1, characterized in that the tool is an ointment, gel, cream or emulsion.

 

Same patents:
The invention relates to medicine, in particular to urology and andrology, and for the treatment of conditions associated with deterioration in the quality of ejaculate

The invention relates to veterinary pharmacology, obstetrics and gynecology
The invention relates to medicine, namely to dermatology and gynecology
The invention relates to medicine, namely to the gynecologist? and can be used to stimulate superovulation in IVF

The invention relates to medicine and relates to a medicinal product for the prevention and treatment of urogenital infections for local use
The invention relates to medicine, gynecology, and can be used for the treatment of menopausal syndrome

The invention relates to medicine, in particular to gynecology and endocrinology, and for the treatment of conditions in women, dependent gonadotropin

The invention relates to veterinary

The invention relates to the field of veterinary medicine

The invention relates to medicine and relates to a medicinal product for the prevention and treatment of urogenital infections for local use

The invention relates to medicine, namely to funds with multifactorial effects on local purulent-inflammatory processes of the skin and mucous membranes

The invention relates to the field of pharmacy and applies ointment with anti-inflammatory action

The invention relates to pharmacology and for the treatment of burn wounds

The invention relates to the field of medicine and the pharmaceutical industry and relates to intranasal antiseptic for the treatment of diseases of the nasopharynx

The invention relates to the field of pharmacy and applies ointment with anti-inflammatory action
The invention relates to the field of medicine and for the treatment of skin injuries, wounds, burns and ulcers

The invention relates to medicine, namely to funds with multifactorial effects on local purulent-inflammatory processes of the skin and mucous membranes

The invention relates to immunology and relates to the modulation of expression of TH1/TH2 cytokines and ribavirin ribavirin analogues in activated T-lymphocytes
Up!